The Conversation (0)
Chart
Detailed Quote
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Featured Articles and Interviews
Press Releases
See More Press Releases
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.